MannKind and United Therapeutics Expand Collaboration with Ralinepag DPI Program

What happened

MannKind announced a new program for Ralinepag DPI, a dry powder inhalation of ralinepag for pulmonary hypertension and fibrotic lung diseases, developed in collaboration with United Therapeutics. United Therapeutics made an additional $5 million payment to support rapid advancement and will be the primary manufacturer. MannKind is eligible for up to $35 million in development milestones plus 10% royalties on net sales. The announcement deepens the existing partnership beyond Tyvaso DPI, indicating confidence in MannKind's Technosphere platform. However, as an early-stage program with no near-term revenue, the immediate financial impact is negligible. The news does not address the looming competitive threat from Liquidia's Yutrepia after Tyvaso DPI exclusivity expires, nor the company's fragile balance sheet with a stockholders' deficit. While the Ralinepag DPI program provides long-term diversification optionality, it is insufficient to alter the cautious stance on the stock at current valuations.

Implication

Near-term, the Ralinepag DPI program does not affect 2026 revenue or earnings; it provides a future milestone and royalty opportunity but requires years of development and clinical success. The deepened partnership with United Therapeutics reinforces strategic alignment but further ties MannKind's fate to a single partner. For long-term investors, successful development would diversify the pipeline and reduce concentration risk, but the market is unlikely to price this potential until clinical data emerge. Meanwhile, the core Tyvaso DPI franchise faces exclusivity expiration and competition, and the balance sheet still carries a large deficit. Thus, this news is insufficient to shift the cautious stance; the stock remains a possible sell given the unfavorable risk/reward.

Thesis delta

The previous thesis centered on Tyvaso DPI concentration and balance sheet fragility. The Ralinepag DPI program, if successful, could provide a new revenue stream and diversify away from treprostinil, potentially improving the long-term outlook. However, given its early stage and the immediate overhang of treprostinil competition, the thesis remains largely unchanged; we now have a slightly more positive long-term catalyst but with no near-term impact. The risk of dilution or failure still dominates.